You are here
FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab for metastatic colorectal cancer (FIRE-3): a post-hoc analysis of tumour dynamics in the final RAS wild-type subgroup of this randomised open-label phase 3 trial
Stintzing S, Modest DP, Rossius L, Lerch MM, von Weikersthal LF, Decker T, et al.
Search this site
ECCO2017 symposium webcast: Treatment evolution in advanced GI malignancies
Subscribe to our E-Alert to keep up to date with the new items in the Resource Centre
Interview with Dr. Marianne G. Guren
New Book Content
Leonard L. Gunderson, John H. Donohue, Steven R. Alberts, Jonathan B. Ashman, and Dawn E. JaroszewskiChapter 75 from Abeloff's Clinical Oncology (5th Edition)
Julian A. Abrams and Michael QuanteChapter 54 from Sleisenger and Fordtran’s Gastrointestinal and Liver Disease (10th Edition)
This online Resource Centre has been sponsored by Lilly Oncology
Note that Lilly Oncology has no editorial control over the content of this Resource Centre. The Resource Centre and all content therein has been subject to an independent editorial review.